Akebia Therapeutics Valuation
Is AKBA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Sales vs. similares
Price-To-Sales vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of AKBA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: Datos insuficientes para calcular el valor razonable de AKBA para el análisis de valoración.
Muy por debajo del valor justo: Datos insuficientes para calcular el valor razonable de AKBA para el análisis de valoración.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AKBA?
Other financial metrics that can be useful for relative valuation.
| What is AKBA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$341.28m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | -58.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AKBA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.9x | ||
ENTA Enanta Pharmaceuticals | 4.7x | 1.6% | US$360.1m |
MGX Metagenomi | 8.6x | -2.2% | US$405.5m |
ORGO Organogenesis Holdings | 0.8x | 6.4% | US$369.5m |
MGTX MeiraGTx Holdings | 25.3x | 44.3% | US$373.1m |
AKBA Akebia Therapeutics | 1.7x | 17.9% | US$341.3m |
Price-To-Sales vs. similares: AKBA es un buen valor basado en su Ratio Price-To-Sales (1.4x) comparado con la media de sus homólogos (2.4x).
Price to Earnings Ratio vs Industry
How does AKBA's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs. Industria: AKBA es un buen valor basado en su Ratio Price-To-Sales (1.4x) comparado con la media del sector US Biotechs (13.9x).
Price to Sales Ratio vs Fair Ratio
What is AKBA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.7x |
| Fair PS Ratio | 5.3x |
PM vs. Ratio Justo: AKBA es un buen valor basado en su Ratio Price-To-Sales (1.4x) comparado con el Ratio estimado Fair Price-To-Sales (2.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$1.58 | US$5.00 +216.5% | 16.3% | US$6.00 | US$4.00 | n/a | 3 |
| Mar ’25 | US$1.71 | US$4.33 +153.4% | 10.9% | US$5.00 | US$4.00 | n/a | 3 |
| Feb ’25 | US$1.71 | US$4.33 +153.4% | 10.9% | US$5.00 | US$4.00 | n/a | 3 |
| Jan ’25 | US$1.24 | US$4.33 +249.5% | 10.9% | US$5.00 | US$4.00 | n/a | 3 |
| Dec ’24 | US$1.07 | US$4.33 +305.0% | 10.9% | US$5.00 | US$4.00 | n/a | 3 |
| Nov ’24 | US$0.88 | US$3.88 +339.3% | 3.2% | US$4.00 | US$3.75 | n/a | 2 |
| Oct ’24 | US$1.14 | US$3.88 +239.9% | 3.2% | US$4.00 | US$3.75 | n/a | 2 |
| Sep ’24 | US$1.33 | US$3.88 +191.4% | 3.2% | US$4.00 | US$3.75 | n/a | 2 |
| Aug ’24 | US$1.84 | US$3.00 +63.0% | 33.3% | US$4.00 | US$2.00 | n/a | 2 |
| Jul ’24 | US$0.92 | US$3.00 +227.9% | 33.3% | US$4.00 | US$2.00 | n/a | 2 |
| Jun ’24 | US$1.09 | US$3.00 +175.2% | 33.3% | US$4.00 | US$2.00 | n/a | 2 |
| Apr ’24 | US$0.56 | US$1.63 +190.0% | 23.1% | US$2.00 | US$1.25 | US$1.63 | 2 |
| Mar ’24 | US$0.91 | US$1.63 +77.6% | 23.1% | US$2.00 | US$1.25 | US$1.71 | 2 |
| Feb ’24 | US$0.67 | US$1.63 +142.5% | 23.1% | US$2.00 | US$1.25 | US$1.71 | 2 |
| Jan ’24 | US$0.58 | US$1.63 +181.6% | 23.1% | US$2.00 | US$1.25 | US$1.24 | 2 |
| Dec ’23 | US$0.29 | US$1.63 +456.3% | 23.1% | US$2.00 | US$1.25 | US$1.07 | 2 |
| Nov ’23 | US$0.27 | US$1.63 +499.6% | 23.1% | US$2.00 | US$1.25 | US$0.88 | 2 |
| Oct ’23 | US$0.32 | US$1.63 +413.9% | 23.1% | US$2.00 | US$1.25 | US$1.14 | 2 |
| Sep ’23 | US$0.37 | US$1.63 +338.7% | 23.1% | US$2.00 | US$1.25 | US$1.33 | 2 |
| Aug ’23 | US$0.38 | US$1.63 +323.7% | 23.1% | US$2.00 | US$1.25 | US$1.84 | 2 |
| Jul ’23 | US$0.39 | US$1.63 +317.7% | 23.1% | US$2.00 | US$1.25 | US$0.92 | 2 |
| Jun ’23 | US$0.35 | US$1.42 +303.7% | 30.0% | US$2.00 | US$1.00 | US$1.09 | 3 |
| May ’23 | US$0.42 | US$1.75 +321.5% | 24.7% | US$2.00 | US$1.00 | US$0.87 | 4 |
| Apr ’23 | US$0.67 | US$1.75 +162.1% | 24.7% | US$2.00 | US$1.00 | US$0.56 | 4 |
Pronóstico de los analistas: El precio objetivo es más de un 20% superior al precio actual de la acción, pero los analistas no están de acuerdo en un rango estadísticamente seguro.